We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Efficacy of IMPACT in Infant Siblings of Children With ASD (IMPACT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03274622
Recruitment Status : Recruiting
First Posted : September 7, 2017
Last Update Posted : September 7, 2017
National Institute on Deafness and Other Communication Disorders (NIDCD)
Information provided by (Responsible Party):
Paul Yoder, Vanderbilt University

Brief Summary:
Over a 5 year period infant and baby siblings of children with autism spectrum disorders (ASD) will be recruited to this study and will be randomized into 2 groups. Parents of the intervention group will receive 6 week of coaching in how to implement this intervention. Parents randomized to the control group will not receive intervention coaching. Both groups will attend a series of clinic appointments for data collection that occur at 3 month intervals over a 9 month period.

Condition or disease Intervention/treatment
Autism Spectrum Disorder Behavioral: Impact Parent Training Behavioral: No Impact

Detailed Description:

This two-site randomized controlled trail (RCT) will include a sample of 120 siblings of children with ASD (Sibs-ASD) (11 months, 15 days to 18 months, 15 days) who are stratified on initial cumulative-risk status for communication disorder and then randomly assigned to Ingersoll's Improving Parents As Communication Teachers (ImPACT; Ingersoll & Dvortcsak, 2010) treatment or to a business-as-usual (BAU) control condition. The following hypotheses will be tested:

  1. Compared to the BAU Control, children assigned to the ImPACT group will show (a) more growth on pivotal skills and language level, and (b) a lesser degree of ASD symptomatology and language delay.
  2. Pretreatment, cumulative-risk level will statistically interact with (i.e., moderate) treatment assignment to predict children's (a) change in pivotal skills and language, and (b) severity of autism symptoms and language delay.
  3. Compared to the BAU Control, parents in ImPACT will have more optimal parenting stress and parenting efficacy, at least in parents with average or below average depressive symptoms prior to treatment (i.e., depressive symptoms will moderate the effect of ImPACT on parental stress and parenting efficacy).
  4. The effect that ImPACT has on growth of pivotal skills and language will be mediated by parents' frequency and fidelity of use of ImPACT strategies at immediate post-treatment.
  5. The effect of ImPACT on degree of children's language delay and ASD symptomatology at 6 months post-treatment will be mediated by their pivotal skill level at 3 months post-treatment.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 120 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Efficacy of Parent-implemented Treatment in Infant Siblings of Children With Autism Spectrum Disorder (ASD)
Actual Study Start Date : February 16, 2016
Estimated Primary Completion Date : August 30, 2019
Estimated Study Completion Date : August 30, 2019

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Experimental: Impact Parent Training
Parents receive 12 2-hour sessions with a Speech Language pathologist coaching them in the implementation of the Impact intervention
Behavioral: Impact Parent Training
Placebo Comparator: No Impact
No parent coaching is provided
Behavioral: No Impact

Primary Outcome Measures :
  1. Communication [ Time Frame: Change between baseline and 9 months after entry ]
    The combined weighted frequency of intentional communication from the CSBS and BOSCC

Secondary Outcome Measures :
  1. Play [ Time Frame: Change from Baseline to 9 months after entry ]
    average of z scores from Developmental Play Assessment and CSBS play scale

  2. Motor imitation [ Time Frame: Change from Baseline to 9 months after entry ]
    the sum of the scores from the SSIS and the ALIT

  3. Autism social affect symptomatology [ Time Frame: 9 months after entry ]
    average of z scores from BOSCC and CSBS

  4. Language [ Time Frame: 9 months after entry ]
    average of z scores from MCDI and Mullen

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   12 Months to 18 Months   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Younger sibling of a child with ASD who are walking -

  1. Age: 11 months, 15 days to 18 months, 15 days
  2. Older biological sibling: Must have a diagnosis of Autism from UW or VU, which is confirmed via record review. If the older sibling was not diagnosed at UW or VU, then a diagnostic appointment must be made for the older sibling at the corresponding institution in order to confirm the diagnosis of ASD. Half-siblings are ok.
  3. Vision - WNL corrected
  4. Hearing - WNL corrected
  5. Motor: The child must be able to sit independently while picking up objects and giving them to another person.
  6. Ambulatory


No primary motor impairment. No feeding tubes. No other neurological or genetic conditions. Primary language exposure: The primary parent speak to the child using English 50% of the time, and process.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03274622

Contact: Catherine Bush, M.A.CCC SLP 615/322-5127 catherine.t.bus@vanderbilt.edu

United States, Tennessee
Vanderbilt University Recruiting
Nashville, Tennessee, United States, 37232
Principal Investigator: Paul J. Yoder, Ph.D.         
United States, Washington
University of Washington Recruiting
Seattle, Washington, United States, 98195-7920
Contact: Wendy Stone, Ph.D.    206-685-2821    stonew@uw.edu   
Principal Investigator: Wendy Stone, Ph.D.         
Sponsors and Collaborators
Vanderbilt University
National Institute on Deafness and Other Communication Disorders (NIDCD)
Principal Investigator: Paul J. Yoder, Ph.D. Vanderbilt University

Responsible Party: Paul Yoder, Professor, Vanderbilt University
ClinicalTrials.gov Identifier: NCT03274622     History of Changes
Other Study ID Numbers: 140924
1R01DC013767-01 ( U.S. NIH Grant/Contract )
First Posted: September 7, 2017    Key Record Dates
Last Update Posted: September 7, 2017
Last Verified: September 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Autism Spectrum Disorder
Child Development Disorders, Pervasive
Neurodevelopmental Disorders
Mental Disorders